Advances in Multidisciplinary Management of Lung Cancer in China and the U.S.
November 3, 2018 | 8:30am - 5:00pm
Stanford Center at Peking University, Beijing, China
8:30 am  Welcome and Introductions
   Gloria Kim, MD, Stanford University School of Medicine
   Lloyd Minor, MD, Dean Stanford University School of Medicine
   Raymond Pao, Founder, Chi-Li Pao Foundation
   Arthur Sung, MD, FCCP, Stanford University School of Medicine

8:35 am  Societal Burden of Air-Pollution, Cigarette Smoking and Association With Lung Cancer
   Cigarette Smoking, Air pollution, and Lung Cancer Statistics in the US
   Arthur Sung, MD, FCCP, Stanford University School of Medicine

8:55 am  Lung Cancer Screening
   NLST And Lung Cancer Screening In US, Barriers To Implementation
   Ann Leung, MD, Stanford University School of Medicine

9:15 am  Q & A

9:25 am  Diagnosis and Staging

9:25 am  Non-Invasive Staging of NSCLA (CT and PET)
   Ann Leung, MD, Stanford University School of Medicine

9:40 am  Interventional Technologies of Lung Cancer in the Era of Precision Medicine
   Guangfa Wang, MD, PhD, Peking University First Hospital

10:00 am  EBUS Staging of Mediastinum and Beyond
   Meghan Ramsey, MD, Stanford University School of Medicine

10:20 am  Liquid Biopsy - Current State and Future
   Maximilian Diehn, MD, PhD, Stanford University School of Medicine

10:40 am  Surgical Staging, and Standard Practice in China
   Keneng Chen, MD, PhD, Peking University School of Oncology

10:55 am  Q & A

11:05 am  Break
Program Continued

**Treatment | Local**

11:15 am  Diagnosis and Management of Ground Glass Nodule  
Keneng Chen, MD, PhD, Peking University School of Oncology

11:35 am  Treatment of Multifocal Lepidic Adenocarcinoma  
Joseph Shrager, MD Stanford University School of Medicine

11:55 pm  Precision Radiotherapy for Lung Cancer  
Jinming Yu, MD, PhD, Shandong Cancer Hospital Affiliated to Shandong University

12:15 pm  The Expanding Role of Radiation Therapy for Stage I-IV Lung Cancer  
Billy Loo, MD, PhD, DABR, Stanford University School of Medicine

12:35 pm  Optimal Combined Modality Therapy for Lung Cancer: Evidence from Randomized Trials in China and Globally  
Luhua Wang, MD, Peking Union Medical College

12:55 pm  Q & A

1:05 pm  **Lunch**

**Treatment | Systemic**

1:50 pm  Focused Targeted Therapy - EGFRI Mutation and Management  
Heather Wakelee, MD, Stanford University School of Medicine

2:10 pm  Focused Targeted Therapy - Management of ALK+NSCLC  
Joel Neal, MD, PhD, Stanford University School of Medicine

2:30 pm  Focused Targeted Therapy - ROS1, MET, and Emerging Targets  
Ying Liang, MD, PhD, Sun Yat-sen University Cancer Center

3:00 pm  Immunology of NSCLC and Immunotherapy  
Shun Lu, MD, PhD, Shanghai Chest Hospital, Jiao Tong University

3:30 pm  Gene Editing in Lung Cancer - CRISPR/Cas9 Technology and EGFR Mutations  
You Lu, MD, West China Hospital, Sichuan University

4:00 pm  Q & A

4:10 pm  Break

4:20 pm  **Panel Discussion**

5:05 pm  **Concluding Remarks**

5:10 pm  **Mixer**

5:30 pm  **Dinner Reception**
Keneng Chen, MD, PhD
Professor, Chair of the First Department of Thoracic Surgery
Peking University School of Oncology

Professor Keneng Chen received a master's degree in oncology and a doctor degree in thoracic surgery from School of Medicine in Wuhan University. He is a PhD and MD supervisor in oncology and Director of Thoracic Surgery at the Beijing Cancer Hospital of Peking University. Professor Chen is dedicated to promoting thoracic surgery as one key part of multidisciplinary treatment of lung cancer, developing minimally invasive lung cancer surgery in China, and setting up new multidisciplinary groups to improve the quality of life for cancer patients.

Maximilian Diehn, MD, PhD
Associate Professor of Radiation Oncology - Radiation Therapy
Stanford University School of Medicine

Dr. Maximilian Diehn received his bachelor's degree in biochemical sciences from Harvard College and his MD and PhD in biophysics from Stanford University. He is a board certified radiation oncologist, specializing in the treatment of lung cancers. Dr Diehn’s research program spans laboratory, translational, and clinical studies. His areas of interest include cancer genomics, stem cell biology, and lung cancer biology. His group has developed an ultrasensitive and specific method of detection of circulating tumor DNA called CAPP-Seq. Current work is focused on applying CAPP-Seq to a range of clinical contexts, with an emphasis on minimal residual disease and early detection.

Ann N.C. Leung, MD
Professor and Associate Chair of Radiology
Stanford University School of Medicine

Professor Ann Leung graduated from McGill University with a bachelor of science degree in biochemistry. She completed her medical school studies and residency training in radiology at the University of British Columbia. Her fellowship training in thoracic radiology was divided between the University of Kyoto and L'Hôpital Pitié-Salpêtrière in Paris. Professor Leung is currently Associate Chair of Clinical Affairs, and Division Head of Thoracic Imaging in the Department of Radiology at Stanford University Medical Center. Her research interests focus on the use of computed tomography to diagnose and evaluate thoracic diseases, including lung cancer. Professor Leung is a past President of the Society of Thoracic Radiology and serves on several national committees responsible for the development of clinical practice guidelines for lung cancer screening and management of pulmonary nodules.
Dr. Ying Liang specializes in the medical treatment of thoracic malignancies. In addition to her education and training in China, Dr. Liang was a post-doctoral fellow at the Stanford Cancer Institute from 2013 to 2014. She has authored or co-authored more than 50 peer-reviewed articles in major international scientific journals. She has also participated in many international randomized control studies, clinical trials and Phase I trials. She is a member of the International Association for the Study of Lung Cancer.

Dr. Billy Loo, is Associate Professor of Radiation Oncology at Stanford University. He is a physician-scientist Radiation Oncologist and Bioengineer who leads the Thoracic Radiation Oncology Program. Dr. Loo is an internationally recognized expert in thoracic cancers, specializing in state-of-the-art radiation therapy for lung/thoracic cancers, including stereotactic ablative radiotherapy (SABR) and 4-D image-guided radiation therapy. Dr. Loo’s clinical research is in clinical trials and implementation of new treatment techniques for lung cancer, development of new imaging biomarkers of physiologic function and cancer treatment response, and new clinical applications of SABR. His laboratory research focus is to co-lead a collaboration between Stanford Cancer Institute and SLAC National Accelerator Laboratory to develop PHASER, a next-generation ultra-rapid radiation therapy technology, and study the radiobiology of extremely rapid FLASH radiation therapy.

Professor Shun Lu holds a medical degree and a doctoral degree in medical oncology from Fudan University. Professor Lu is involved in patient care as well as the development of new drugs in China through his work on clinical trials examining targeted therapies and immunotherapy for lung cancer. He is a member of the China State Food and Drug Administration Expert Panel, Commissioner of the Oncology Society of the Chinese Medical Association Shanghai, Director of Chinese Lung Cancer Study Association, and Standing Director & Deputy Secretary of Chinese Society of Clinical Oncology. He is recognized internationally and serves as a member of ASCO International Affairs Committee. He has published more than 200 peer-reviewed articles in major international scientific journals.
You Lu, MD
Professor and Chair of Department of Thoracic Cancer
Cancer Center, West China Hospital
Sichuan University

Professor You Lu is Vice President of Experts Committee on Non-Small Cell Lung Cancer of Chinese Society of Clinical Oncology. He is a member of the Consultative Committees of Antitumor Pharmaceuticals Register and Review, Centre of Drug Evaluation, and China Food and Drug Administration. He is President of the Sichuan Cancer Society, chair of the Sichuan Medical Society for Radiation Oncology, and chief expert of the Health Committee of Sichuan Province. Professor Lu serves as an expert for the development of China’s national guidelines for the diagnosis and treatment of primary lung cancer. He has contributed as an author to over 70 articles and a peer reviewer for major international peer-reviewed scientific journals.

Joel Neal, MD, PhD
Assistant Professor of Oncology
Stanford University School of Medicine

Dr. Joel Neal holds a medical degree and a doctoral degree in tumor cell biology from Northwestern University. He completed a fellowship in oncology, rotating through the Dana-Farber Cancer Institute and Massachusetts General Hospital. In addition to maintaining an active practice, he focuses on the design and conduct of clinical trials involving targeted therapies and immunotherapy for lung cancer and mesothelioma. He has published dozens of articles in the field of thoracic oncology. He is a member of the International Association of the Study of Lung Cancer and is a study chair and thoracic core committee member within the ECOG-ACRIN cooperative group.

Meghan Ramsey, MD
Clinical Assistant Professor of Pulmonary and Critical Care Medicine
Stanford University School of Medicine

Dr. Meghan Ramsey completed her medical degree, internal medicine residency, and pulmonary/critical care fellowship at Stanford University. Dr. Ramsey specializes in interventional pulmonology, with an emphasis on the diagnosis and management of thoracic malignancies and pleural disease. After spending intensive training in value-based healthcare delivery innovation, Dr. Ramsey currently focuses on improving the quality of pulmonary care for all oncology patients through innovative practice centered on lung cancer screening and prevention, and brings high-quality care to many patients through outreach.
Joseph Shrager, MD  
Professor and Chief, Stanford Division of Thoracic Surgery  
Stanford University School of Medicine

Professor Shrager received his medical degree from Harvard Medical School, and trained in general surgery at University of Pennsylvania and thoracic surgery at Massachusetts General Hospital. After 10 years on faculty at University of Pennsylvania, he accepted his current position at Stanford. Professor Shrager’s main clinical interests are lung cancer, surgery for emphysema, and mediastinal diseases/tumors. He has published many articles addressing lung-sparing and minimally invasive resections for lung cancer, the management of multifocal adenocarcinoma of the lung, transcervical thymectomy for myasthenia gravis, and lung volume reduction surgery. Dr. Shrager also directs a basic/translational research laboratory focused upon the responses of the diaphragm to various disease states and interventions.

Arthur Sung, MD, FCCP  
Clinical Associate Professor of Pulmonary Medicine and Critical Care Medicine  
Director, Interventional Pulmonology and Bronchoscopy  
Stanford University School of Medicine

Dr. Arthur Sung is the Director of Interventional Pulmonology and Bronchoscopy at Stanford HealthCare and also the Associate Chief of the Pulmonary and Critical Care Division at Stanford. His clinical interests include lung cancers and molecular testing of small samples acquired by means of minimally invasive approaches, the functional imaging of the central and peripheral airways, and epigenetics of lung cancer pathogenesis. He is integrally involved in leading strategic efforts for programmatic expansion of the division regionally, as well as overseeing quality projects in pulmonary medicine.

Heather Wakelee, MD  
Professor of Oncology  
Stanford University School of Medicine

Professor Heather Wakelee leads the thoracic medical oncology research program at Stanford. She is the Faculty Director of the Stanford University Cancer Clinical Trials Office. Professor Wakelee’s clinical research is focused on thoracic malignancies including lung cancer and thymic malignancies. Professor Wakelee has led multiple investigator-initiated protocols and played a central role in clinical trials with bevacizumab and many other anti-angiogenic agents, including as the principal investigator of the multinational E105 study of adjuvant bevacizumab in NSCLC. She is also interested in lung cancer in never-smokers and novel lung cancer biomarkers. She has authored or co-authored over 100 medical articles on thoracic malignancies.
Speakers | continued

**Guangfa Wang, MD, PhD**
Professor and Chief of Pulmonary and Critical Care Medicine  
Peking University First Hospital

Professor Guangfa Wang is Chief of the Department of Pulmonary and Critical Care Medicine at Peking University First Hospital. He is the head of bronchoscopy and interventional pulmonology group of the Chinese Thoracic Society and has been selected as executive board member for Promoting the Art & Science of Bronchoology and Interventional Pulmonology (WABIP) since 2016. Professor Wang has been instrumental in the standardization of interventional pulmonology methods in China, including bronchoscopic diagnostic technologies, management of central airway stenosis, and rigid bronchoscopy. He has published many peer-reviewed papers in the areas of interventional pulmonology, sleep medicine, and air pollution related issues in China.

---

**Luhua Wang, MD**  
Professor of Radiation Oncology  
Vice President of Cancer Hospital  
Chinese Academy of Medical Sciences & Peking Union Medical College

Professor Luhua Wang received a bachelor’s degree in medicine from Bengbu Medical College, and a master’s degree in from Peking Union Medical College. His research interests are in tumor radiobiology and he is an expert in the development and application of hyperfractionated radiation. He currently is engaged in the clinical application and research of radiotherapy for the treatment of chest tumors, the comprehensive treatment for lung cancer and esophageal cancer, and the clinical application of three-dimensional conformal radiation therapy. He has published more than 60 articles in radiation oncology.

---

**Jinming Yu, MD, PhD**  
Professor, President  
Shandong Cancer Hospital Affiliated to Shandong University

Professor Jinming Yu is an Academician of Chinese Academy of Engineering. In addition to his key academic role in the innovation of radiotherapy, he is the President of Shandong Cancer Hospital, a major contributor to medicine nationally as a leader in the Shandong Academy of Medical Sciences, the China Anti-Cancer Association and the Professional Committee of Chinese Radiation Oncology. He focuses on developing new radiation therapies and exploring biological targets on thoracic diseases, including lung cancer, breast cancer and esophagus cancer. He has authored over 200 peer-reviewed articles in the radiotherapy related areas.